however, oral drugs need further data in order to confirm their status as a true alternative to injectables
While side effects such as nausea and dizziness are more common, they are generally manageable and should be weighed against the potential metabolic improvements
These medications were initially developed for type 2 diabetes, and more recently have been approved for weight management, because they can reduce appetite, slow gastric emptying, and improve insulin sensitivity
No published Phase I trial establishing tolerability, human pharmacokinetics or dose escalation was identified
Our Longevity Panel and Comprehensive Metabolic Panel are designed to characterise the hormonal and metabolic baseline that should inform any peptide protocol not as a formality, but as the clinical foundation on which a safe and effective intervention can be built